-
Je něco špatně v tomto záznamu ?
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
LK. Mercer, AC. Regierer, X. Mariette, WG. Dixon, E. Baecklund, K. Hellgren, L. Dreyer, ML. Hetland, R. Cordtz, K. Hyrich, A. Strangfeld, A. Zink, H. Canhao, MV. Hernandez, F. Tubach, JE. Gottenberg, J. Morel, J. Zavada, F. Iannone, J. Askling,...
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest)
od 1939-01-01 do Před 6 měsíci
- MeSH
- antirevmatika terapeutické užití MeSH
- B-buněčný lymfom epidemiologie etiologie MeSH
- inhibitory TNF MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom T-buněčný epidemiologie etiologie MeSH
- lymfom epidemiologie etiologie patologie MeSH
- nehodgkinský lymfom epidemiologie etiologie MeSH
- registrace MeSH
- revmatoidní artritida komplikace farmakoterapie MeSH
- rizikové faktory MeSH
- tumor nekrotizující faktory MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD. RESULTS: Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population. CONCLUSION: This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.
Arthritis Research UK Centre for Epidemiology University of Manchester Manchester UK
Clinical Epidemiology Unit Karolinska Institutet Stockholm Sweden
Department of Medical Sciences Uppsala University Uppsala Sweden
Department of Rheumatology CHU Strasbourg Strasbourg France
Department of Rheumatology Hospital Clinic of Barcelona Barcelona Spain
Epidemiology Unit German Rheumatism Research Centre Berlin Germany
Institute of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016413
- 003
- CZ-PrNML
- 005
- 20180515103818.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2017-211623 $2 doi
- 035 __
- $a (PubMed)28822981
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mercer, Louise K $u Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK.
- 245 10
- $a Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project / $c LK. Mercer, AC. Regierer, X. Mariette, WG. Dixon, E. Baecklund, K. Hellgren, L. Dreyer, ML. Hetland, R. Cordtz, K. Hyrich, A. Strangfeld, A. Zink, H. Canhao, MV. Hernandez, F. Tubach, JE. Gottenberg, J. Morel, J. Zavada, F. Iannone, J. Askling, J. Listing,
- 520 9_
- $a BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD. RESULTS: Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population. CONCLUSION: This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.
- 650 _2
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a revmatoidní artritida $x komplikace $x farmakoterapie $7 D001172
- 650 _2
- $a Evropa $x epidemiologie $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom $x epidemiologie $x etiologie $x patologie $7 D008223
- 650 _2
- $a B-buněčný lymfom $x epidemiologie $x etiologie $7 D016393
- 650 _2
- $a nehodgkinský lymfom $x epidemiologie $x etiologie $7 D008228
- 650 _2
- $a lymfom T-buněčný $x epidemiologie $x etiologie $7 D016399
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a tumor nekrotizující faktory $7 D048069
- 650 _2
- $a inhibitory TNF $7 D000079424
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Regierer, Anne C $u Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
- 700 1_
- $a Mariette, Xavier $u Department of Rheumatology, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, Paris, France.
- 700 1_
- $a Dixon, William G $u Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK.
- 700 1_
- $a Baecklund, Eva $u Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Hellgren, Karin $u Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Dreyer, Lene $u Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark. The Parker Institute, Frederiksberg, Denmark.
- 700 1_
- $a Hetland, Merete Lund $u DANBIO, Copenhagen Center for Arthritis Research, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Cordtz, René $u Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark. The Parker Institute, Frederiksberg, Denmark.
- 700 1_
- $a Hyrich, Kimme $u Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK. Musculoskeletal Biomedical Research Unit, National Institute of Health Research Manchester, Central Manchester NHS Foundation Trust, Manchester Academic Health Science, Manchester, UK.
- 700 1_
- $a Strangfeld, Anja $u Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
- 700 1_
- $a Zink, Angela $u Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany. CharitéUniversitätsmedizin Berlin, Berlin, Germany.
- 700 1_
- $a Canhao, Helena $u EpiDoC Unit, Universidade Nova de Lisboa, CEDOC, NOVA Medical School and National School of Public Health, Lisbon, Portugal.
- 700 1_
- $a Hernandez, M Victoria $u Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain.
- 700 1_
- $a Tubach, Florence $u Département of BIOSPIM, Département BIOSPIM Hôpital Pitié-Salpétrière, AP-HP, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France.
- 700 1_
- $a Gottenberg, Jacques-Eric $u Department of Rheumatology, CHU Strasbourg, Strasbourg, France.
- 700 1_
- $a Morel, Jacques $u Department of Rheumatology, University of Montpellier and Teaching Hospital Lapeyronie, Montpellier, France.
- 700 1_
- $a Zavada, Jakub $u Institute of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Iannone, Florenzo $u Rheumatology Unit, University of Bari, Bari, Italy.
- 700 1_
- $a Askling, Johan $u Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Listing, Joachim $u Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 12 (2017), s. 2025-2030
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28822981 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515103951 $b ABA008
- 999 __
- $a ok $b bmc $g 1300037 $s 1013253
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 76 $c 12 $d 2025-2030 $e 20170819 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20180515
